Open AccessPrognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases
Author(s) -
Ali İnal,
Hilmi Kodaz,
Hatice Odabaş,
Ayşe Ocak Duran,
Mehmet Şeker,
M. İnanc,
Emin Tamer Elkıran,
Yusuf Günaydın,
Serkan Menekşe,
Turkan Ozturk Topcu,
Zuhat Urakçı,
Didem Taştekin,
Mehmet Bilici,
Şener Cihan,
Çağlayan Geredeli,
Emel Sezer,
Doğan Uncu,
Erkan Arpacı,
Bayram Öztürk,
Öznur Bal,
Mükremın Uysal,
Özgür Tanrıverdi,
Mahmut Gümüş,
Bala Basak Oven Ustaalioğlu,
Ali Süner,
Suna Çokmert,
İlhan Hacıbekiroğlu,
Kübra Aydın,
Abdurrahman Işıkdoğan
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.176417
Subject(s) - medicine , univariate analysis , multivariate analysis , oncology , lung cancer , proportional hazards model , chemotherapy , prophylactic cranial irradiation , radiation therapy , brain metastasis , survival analysis , hazard ratio , prognostic variable , cancer , radiology , metastasis , conventional pci , myocardial infarction , confidence interval
Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the median survival is only 1 month. However, it is difficult to treat brain metastases with systemic chemotherapy since the agents have difficulty crossing the blood-brain barrier. Therefore, it is important to estimate the patient's survival prognosis. The aim of this study was to analyze prognostic factors for survival in Turkish patients who received chemotherapy after cranial irradiation for NSCLC with brain metastases.